Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00046488
Status:
COMPLETED
Last Update Posted:
2013-09-16
First Post:
2002-09-30
Brief Title:
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia CLL
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Phase I Multicenter Dose-Escalation Study of IDEC-152 Anti-CD23 Monoclonal Antibody in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2010-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine what side effects and what clinical effects if any the administration of this investigational product IDEC-152 an antibody against CD23 which is an important protein on leukemia cells and certain cells in the bodys immune system has on the CLL patient population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None